Form 4: CorMedix Director Alan Dunton Receives Stock Units

CorMedix Inc. Director Alan W. Dunton reported the acquisition of 30,453 restricted stock units, vesting in January 2027.

Summary

• Alan W. Dunton, a Director of CorMedix Inc. (CRMD), acquired 30,453 shares of common stock.
• These shares represent restricted stock units (RSUs) issued on January 26, 2026.
• Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock.
• The restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.
• Following this transaction, Alan Dunton beneficially owns 70,703 shares of common stock.
• A Power of Attorney was granted by Alan Dunton to Beth Zelnick Kaufman on January 14, 2026, to handle SEC filings (Forms ID, 3, 4, 5, 144) on his behalf.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a director, which is a neutral event but can be seen as slightly positive as it aligns management's interests with shareholders and incentivizes continued service. It does not contain significant financial news or operational updates.

Positives

• Director Alan Dunton received 30,453 restricted stock units, aligning his interests with shareholders.
• The vesting schedule encourages continued service and long-term commitment from a key director.

Risks

• The vesting of the restricted stock units is contingent upon Alan Dunton's continued service to CorMedix Inc. until the vesting date of January 26, 2027. If service ceases before this date, the units may not vest.

Future Outlook

The restricted stock units are expected to vest in full on January 26, 2027, provided Alan Dunton continues his service to CorMedix Inc. until that date.

Management Comments

• The Power of Attorney states that actions taken by the attorney-in-fact are considered to be of benefit to, in the best interest of, or legally required by, the undersigned (Alan Dunton).

Industry Context

The issuance of restricted stock units to directors is a common practice in the biotechnology and pharmaceutical industry, aligning executive incentives with long-term shareholder value and promoting retention. This type of equity compensation is standard for publicly traded companies.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard form of equity compensation, comparable to practices at other publicly traded companies in the pharmaceutical sector.
• Similar RSU grants are common at companies like Pfizer, Moderna, or Johnson & Johnson for their non-executive directors, typically tied to service periods to ensure retention and alignment.
• The specific number of units (30,453) would need to be benchmarked against CorMedix's size, director compensation policies, and peer group practices to assess its relative generosity, but the mechanism itself is standard.

Related Party Transactions

• The grant of restricted stock units to Alan Dunton, a director of CorMedix Inc., constitutes a related party transaction as he is an insider.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, potentially encouraging long-term value creation. Future dilution from share issuance upon vesting is minimal given the number of shares.
• Management: The Power of Attorney streamlines SEC filing processes for the director, ensuring timely compliance.

Next Steps

• Vesting of the 30,453 restricted stock units on January 26, 2027, subject to continued service.

Key Dates

Recommendation

This filing details a routine equity compensation grant to a director and an administrative power of attorney. It does not contain information that would fundamentally alter the investment thesis for CorMedix Inc. While director ownership alignment is generally positive, this specific transaction is not significant enough to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

CorMedix, CRMD, Alan Dunton, Director, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Compensation